title: [Pulmonary fibrosis and endovesical mitomycin C].
abstract: The Mitomycin C is a chemotherapeutic agent used in several types of carcinomas. In the superficial vesical carcinoma comes using since more than a quarter century in the form of endovesical instillations. It is a drug relatively safe, although there have been described adverse effects related to its systemic administration as myelosuppression, anaemia, kidney toxicity and less frequently pulmonary fibrosis. In this article we presented the case of a patient who suffers a respiratory illness compatible with interstitial lung disease that develops a respiratory severe insufficiency finishing with the death, after the administration of endovesical mitomycin C, being this adverse effect exceptional for this route of administration.
authors.affiliation: Servicio de Urología, Hospital Juan Canalejo, La Coruña, España. janeiropais@canalejo.org
authors.forename: José M
authors.initials: JM
authors.lastname: Janeiro Pais
authors.forename: Vicente Pastor
authors.initials: VP
authors.lastname: Casas Agudo
authors.forename: Daniel
authors.initials: D
authors.lastname: López Garcia
authors.forename: Juan
authors.initials: J
authors.lastname: González Dacal
authors.forename: Cipriano
authors.initials: C
authors.lastname: Lamas Meilán
authors.forename: Marcelino
authors.initials: M
authors.lastname: González Martín
mesh_terms: D000283:Administration, Intravesical; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects*; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects*; D011658:Pulmonary Fibrosis / Q000139:chemically induced*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
chemical_list: D000903:Antibiotics, Antineoplastic; D016685:Mitomycin